Title : A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.

Pub. Date : 2008 Apr

PMID : 18056648






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Of 16 patients who discontinued sorafenib and then did not receive any immediate therapy, 10 had postdiscontinuation PSA declines of 7%-52%. Sorafenib kallikrein related peptidase 3 Homo sapiens
2 CONCLUSIONS: Sorafenib has limited activity using current PSA criteria. Sorafenib kallikrein related peptidase 3 Homo sapiens